Patients with the rs3745274 GG genotype may have a decreased, but not absent risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of efavirenz toxicity.